- Trials with a EudraCT protocol (13)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (4)
13 result(s) found for: Childhood absence epilepsy.
Displaying page 1 of 1.
EudraCT Number: 2016-002313-22 | Sponsor Protocol Number: ADV6770-A11CS | Start Date*: Information not available in EudraCT | ||||||||||||||||
Sponsor Name:ADVICENNE PHARMA SA | ||||||||||||||||||
Full Title: A randomised, active controlled, open-label, 2-way cross-over, multicentre study to investigate the palatability, acceptability, pharmacokinetics, safety and tolerability, and treatment compliance ... | ||||||||||||||||||
Medical condition: Children with chilhood absence epilepsy. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001514-29 | Sponsor Protocol Number: LAM115377 | Start Date*: 2017-08-11 | |||||||||||
Sponsor Name:GlaxoSmithKline KK | |||||||||||||
Full Title: A multi-center, uncontrolled, open-label, evaluation of Lamotrigine monotherapy on newly diagnosed typical absence seizures in children and adolescents | |||||||||||||
Medical condition: Typical absence seizure | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002769-33 | Sponsor Protocol Number: EP0132 | Start Date*: 2021-05-28 |
Sponsor Name:UCB Biopharma SRL | ||
Full Title: A Multicenter, Open-Label, Single-Arm Study to Evaluate Long-Term Safety, Tolerability, and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Ju... | ||
Medical condition: Childhood absence epilepsy (CAE) Juvenile absence epilepsy (JAE) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: HU (Prematurely Ended) BE (Completed) IT (Completed) PL (Completed) SK (Completed) Outside EU/EEA RO (Completed) ES (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-002750-24 | Sponsor Protocol Number: N01269 | Start Date*: 2021-04-16 |
Sponsor Name:UCB Biopharma SRL | ||
Full Title: A Randomized, Dose-Finding and Confirmatory, Double-Blind, Placebo-Controlled, Parallel-Group Multicenter Study With a 2-Stage Adaptive Design and Randomized Withdrawal to Evaluate the Efficacy, Sa... | ||
Medical condition: Childhood absence epilepsy and juvenile absence epilepsy | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: PL (Completed) BE (Completed) IT (Trial now transitioned) SK (Trial now transitioned) Outside EU/EEA ES (Trial now transitioned) RO (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2005-003520-18 | Sponsor Protocol Number: LEV05-1 | Start Date*: 2005-07-25 | |||||||||||
Sponsor Name:ISTITUTO C. MONDINO | |||||||||||||
Full Title: Multicenter, double-blind placebo controlled study of levetiracetam in the treatment of childhood and juvenile absence epilepsy. | |||||||||||||
Medical condition: therapy of absence epilepsy | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-003522-26 | Sponsor Protocol Number: LEVFU05-1 | Start Date*: 2005-07-25 | |||||||||||
Sponsor Name:ISTITUTO C. MONDINO | |||||||||||||
Full Title: Open label, multicenter study of levetiracetam in the treatment of childhood and juvenile absence epilepsy | |||||||||||||
Medical condition: Efficacy and tolerability within one year of levetiracetam | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001318-32 | Sponsor Protocol Number: P261-401 | Start Date*: 2011-11-17 | |||||||||||
Sponsor Name:Upsher-Smith Laboratories, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intranasal Midazolam (USL261) in the Outpatient Treatment of Subjects with Seizure Clusters ARTEMIS-1: Acute Rescu... | |||||||||||||
Medical condition: epilepsy | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended) HU (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004456-38 | Sponsor Protocol Number: E2007-G000-236 | Start Date*: 2019-10-31 | |||||||||||
Sponsor Name:Eisai Limited | |||||||||||||
Full Title: An Open-Label Study with Extension Phase to Evaluate the Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Subjects (Age 1 Month to Less Than 18 Years) With Child... | |||||||||||||
Medical condition: Seizures associated with paediatric epilepsy syndromes and partial-onset seizures | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) FR (Trial now transitioned) DE (Trial now transitioned) DK (Completed) BE (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001664-38 | Sponsor Protocol Number: FFA-MAE | Start Date*: 2019-10-02 | |||||||||||
Sponsor Name:University Hospital Schleswig-Holstein (UKSH) | |||||||||||||
Full Title: A proof of concept and assessment of maximal effect study with low dose Fenfluramine as add-on therapy in Myoclonic Astatic Epilepsy (Doose-Syndrome) | |||||||||||||
Medical condition: Childhood epilepsy: Myoclonic Astatic Epilepsy (Doose-Syndrome) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002939-34 | Sponsor Protocol Number: GWEP1424 | Start Date*: 2014-12-29 | |||||||||||
Sponsor Name:GW Research Ltd | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of cannabidiol (GWP42003-P) in children and young adults with Dravet syndrome. | |||||||||||||
Medical condition: Dravet syndrome | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) NL (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001997-13 | Sponsor Protocol Number: N167 | Start Date*: 2004-11-22 | |||||||||||
Sponsor Name:UCB S.A. Pharma Sector | |||||||||||||
Full Title: An open-label, multicenter, follow-up study to evaluate the safety and efficacy of levetiracetam (LEV) (oral tablets of 166, 250 or 500 mg b.i.d.), at individualized doses up to a maximum of 4000 m... | |||||||||||||
Medical condition: Neurology, epilepsy, primary generalized seizures | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) EE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004952-30 | Sponsor Protocol Number: E2080-J081-304 | Start Date*: 2017-02-13 |
Sponsor Name:Eisai Co, Ltd. | ||
Full Title: A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients | ||
Medical condition: Lennox-Gastaut Syndrome (LSG) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2018-002485-39 | Sponsor Protocol Number: TAK-935-18-001(OV935)Amendment1 | Start Date*: 2019-06-14 |
Sponsor Name:Ovid Therapeutics, Inc. | ||
Full Title: A PHASE 2, PROSPECTIVE, INTERVENTIONAL, OPEN-LABEL, MULTI-SITE, EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF TAK-935 (OV935) AS ADJUNCTIVE THERAPY IN PATIENTS WITH RARE EPILEP... | ||
Medical condition: developmental and epileptic encephalopathies | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) PL (Trial now transitioned) PT (Trial now transitioned) Outside EU/EEA | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
